Join the Liver and Pancreatic Disease group to help and get support from people like you.
Liver and Pancreatic Disease News
Ozempic Could Curb Progression of Diabetes-Linked Liver Disease
MONDAY, Sept. 16, 2024 – Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP-1 medicines like Ozempic can help stop that. In...
People With Chronic Liver Disease Face More Barriers to Health Care
THURSDAY, Aug. 29, 2024 – People with chronic liver disease (CLD) have a higher likelihood of barriers to health care, according to a study recently published in Gastro Hep Advances. Carrie R. Wong, ...
Outcomes Similar for Neoadjuvant ICI-Based Therapy, Upfront Surgery for Liver Cancer
THURSDAY, Aug. 22, 2024 – Patients treated with neoadjuvant immune checkpoint inhibitor (ICI)-based therapy for hepatocellular carcinoma (HCC) have higher-risk disease features but achieve outcomes...
New Definition of Steatotic Liver Disease Improves Prediction of Kidney Disease
TUESDAY, Aug. 20, 2024 – Using a new classification of steatotic liver disease (SLD) based on the presence of metabolic dysfunction and alcohol consumption, metabolic dysfunction-associated...
Potentially Hepatotoxic Botanicals Frequently Used in United States
MONDAY, Aug. 5, 2024 – An estimated 15 million U.S. adults consumed at least one of six potentially hepatotoxic botanicals within the previous 30 days, according to a study published online Aug. 5...
Guidelines Updated for Diagnosis, Management of Focal Liver Lesions
TUESDAY, July 23, 2024 – In a clinical guideline issued by the American College of Gastroenterology and published online in the July issue of The American Journal of Gastroenterology, updated...
Facial Temperatures Might Help Docs Diagnose Diabetes, Fatty Liver Disease
WEDNESDAY, July 3, 2024 – Screening for chronic illnesses like diabetes or fatty liver disease could one day be as simple as checking the temperature of your nose, eyes or cheeks. The temperature of...
New Tool Could Spot Liver Cancer Early, Upping Survival
WEDNESDAY, June 19, 2024 – A new AI-driven blood test could improve detection of liver cancer, which is one of the most fatal cancers because early diagnosis is difficult. The test looks for “fusion ...
Childhood Physical Activity Levels Tied to Risk for Liver Disease in Young Adults
WEDNESDAY, June 19, 2024 – Increasing physical activity during childhood may independently lower the risk for liver disease in young adulthood, according to a study published online May 29 in npj ...
Survodutide Tied to Significant Improvement in Fatty Liver Disease
MONDAY, June 17, 2024 – Most patients taking survodutide, a dual agonist of glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor, experience significant improvement in metabolic...
Tirzepatide Beneficial for Resolution of MASH in Patients With MASH, Fibrosis
THURSDAY, June 13, 2024 – For patients with metabolic dysfunction-associated steatohepatitis (MASH) and moderate-to-severe fibrosis, 52 weeks of tirzepatide is more effective than placebo for...
Experimental GLP-1 Med Might Be Breakthrough Against Fatty Liver Disease
MONDAY, June 10, 2024 – An experimental 'supercharged' form of popular GLP-1 weight-loss meds could help ease fatty liver disease, a new trial suggests. The drug under development, survodutide,...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 – For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists (GLP-1 RA) and...